Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05781750 · ClinicalTrials.gov registry record · Phase 2
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
A Phase 2 study, sponsored by Kezar Life Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT05781750 is a Phase 2 study that was terminated before completion, run by Kezar Life Sciences. The registered enrollment target is 84 participants.
The verdict
NCT05781750, a Phase 2 study, was terminated before completion, sponsored by Kezar Life Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
Interventions
- DRUG placebo
- DRUG zetomipzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2023-11-03 |
| Est. Completion | 2024-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05781750
The ClinicalTrials.gov registry entry for NCT05781750 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kezar Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT05781750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05781750 about?
NCT05781750 is a clinical study titled "A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)". The purpose of this study was to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
What is the current status of trial NCT05781750?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2023-11-03. Estimated completion is 2024-11-08.
What interventions are being tested in trial NCT05781750?
The interventions under investigation include: placebo (DRUG), zetomipzomib (DRUG).
Who is sponsoring clinical trial NCT05781750?
This trial is sponsored by Kezar Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.